Filtered By:
Education: Learning
Vaccination: Shingles (Herpes Zoster) Vaccine
This page shows you your search results in order of date.
Order by Relevance | Date
Total 17 results found since Jan 2013.
Fight Aging! Newsletter, June 5th 2023
In conclusion, higher BMR might reduce lifespan. The underlying pathways linking to major causes of death and relevant interventions warrant further investigation.
Betting Against Progress Turns Out Poorly, But Can Work in the Short Term in a Slow Field
https://www.fightaging.org/archives/2023/06/betting-against-progress-turns-out-poorly-but-can-work-in-the-short-term-in-a-slow-field/
Setting oneself up as a spokesperson for "we will not achieve this goal", as the fellow noted here is choosing to do, is a bet against technological progress. A glance at any few decade period in the past two hundred year...
Source: Fight Aging! - June 4, 2023 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
New STELARA ® (ustekinumab) Long-Term Data Support its Established Safety Profile in Inflammatory Bowel Disease and Durable Efficacy in Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, March 4, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced final pooled long-term safety results for STELARA® (ustekinumab) through five years in adults with moderately to severely active Crohn’s disease (CD) and four years in adults with moderately to severely active ulcerative colitis (UC), as well as final four-year clinical and endoscopic outcomes from the UNIFI long-term extension (LTE) study evaluating the efficacy of STELARA for the treatment of adults with moderately to severely active UC.1,2 These data are a part of Janssen’s 22 oral and poster ...
Source: Johnson and Johnson - March 4, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
STELARA ® (ustekinumab) Demonstrated Sustained Symptomatic and Corticosteroid-Free Remission Through Four Years in Adults with Moderately to Severely Active Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced final data from the long-term extension (LTE) of the Phase 3 UNIFI study demonstrating efficacy and safety of STELARA® (ustekinumab) through four years of treatment in adult patients with moderately to severely active ulcerative colitis (UC).1 Among all patients who had achieved clinical responsea with STELARA during induction, 64.9 percent were in symptomatic remissionb after 44 weeks of maintenance. At week 200 (four years), this proportion of patients was 55.2 percent; the majority (96.4 percen...
Source: Johnson and Johnson - October 10, 2022 Category: Pharmaceuticals Source Type: news
What It Really Feels Like to Have Monkeypox
Since the global monkeypox outbreak began in May 2022, more than 22,000 cases have been confirmed in countries around the world. More than 5,000 of those cases have been recorded in the U.S., with many clustered in hotspots including New York and California. The virus, which often results in a blister-like rash and spreads through close contact, has so far predominantly affected men who have sex with men.
Even as cases tick up and monkeypox gains public attention, however, it can still be difficult to find information about testing, treatment, and vaccines. Many people who fear they are at risk or infected are left to seek...
Source: TIME: Health - August 1, 2022 Category: Consumer Health News Authors: Jamie Ducharme, Angela Haupt and Jeffrey Kluger Tags: Uncategorized healthscienceclimate monkeypox Source Type: news
STELARA ® (ustekinumab) Approved by the U.S. Food and Drug Administration to Treat Pediatric Patients with Active Psoriatic Arthritis
HORSHAM, PENNSYLVANIA, August 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved STELARA® (ustekinumab) for the treatment of pediatric patients six years of age and older with active psoriatic arthritis (PsA). This rare disease that resembles adult PsA affects five to eight percent of children and adolescents with chronic inflammatory arthritis.*1-7 Two of the four indications for STELARA now include pediatric patients, further expanding its treatment profile since the first approval in 2009 for adults living with moderate...
Source: Johnson and Johnson - August 1, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Janssen Presents Study Results Showing Clinical Efficacy for TREMFYA ® (guselkumab) and Long-Term Safety Profile for STELARA® (ustekinumab) for Patients Living with Inflammatory Bowel Disease at Digestive Disease Week® 2022
SPRING HOUSE, PENNSYLVANIA, May 24, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 2 GALAXI 1 clinical trial of TREMFYA® (guselkumab) in adult patients with moderately to severely active Crohn’s disease (CD), and from three separate long-term pooled analyses of adult patients with ulcerative colitis (UC) and CD treated with STELARA® (ustekinumab).1,2,3,4 These data are being presented as oral and poster presentations and are among 29 Janssen abstracts presented during the Digestive Disease Week® (DDW) meeting taking place in person and virtually in San Di...
Source: Johnson and Johnson - May 24, 2022 Category: Pharmaceuticals Source Type: news
Janssen Reports Positive Topline Week 48 Phase 2 Results for TREMFYA ® (guselkumab) in Adults With Moderately to Severely Active Crohn's Disease
SPRING HOUSE, PENNSYLVANIA, November 17, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced topline results from the Phase 2 GALAXI 1 clinical trial which showed rates of clinical remission (Crohn’s Disease Activity Index [CDAI]<150) previously reported at week 12 increased at week 48 among adults with moderately to severely active Crohn’s disease (CD) treated with TREMFYA® (guselkumab).1 At week 48, 65 percent of patients receiving TREMFYA achieved clinical remission. TREMFYA is under investigation and not currently approved for the treatment of CD in the U.S.2Janssen previously...
Source: Johnson and Johnson - November 17, 2021 Category: Pharmaceuticals Source Type: news
Janssen Submits Application Seeking U.S. FDA Approval of STELARA ® (ustekinumab) for the Treatment of Pediatric Patients With Juvenile Psoriatic Arthritis
HORSHAM, PENNSYLVANIA, October 8, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking expanded approval of STELARA® (ustekinumab) to treat pediatric patients ages 5 years and older with juvenile psoriatic arthritis (jPsA).The filing is supported by extrapolation of data from nine studies across both adult trials in active PsA and adult and pediatric studies in moderate to severe plaque psoriasis, totaling 3,997 patients evaluated across these closely associated dis...
Source: Johnson and Johnson - October 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
People Are Reporting Unexpected Side Effects After COVID-19 Vaccination —But That’s Actually Normal
Abigail, a 29-year-old from New York City who asked to use a pseudonym to preserve her privacy, knew to expect some side effects after she got her second Pfizer-BioNTech COVID-19 vaccine in February. The fever, body aches and fatigue she felt were nothing surprising. But when she began experiencing heavy, “stupidly painful, debilitating” menstrual periods, she felt blindsided. “I had not heard a single person talking about it,” she says.
While scientists have not confirmed that COVID-19 vaccines can cause menstrual changes like Abigail’s, she feels confident the shot was her trigger, since she...
Source: TIME: Health - April 22, 2021 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized COVID-19 Source Type: news
Fight Aging! Newsletter, May 25th 2020
In conclusion, our results suggest a previously unknown mechanism whereby the canonical NF-κB cascade and a mitochondrial fission pathway interdependently regulate endothelial inflammation.
Lin28 as a Target for Nerve Regeneration
https://www.fightaging.org/archives/2020/05/lin28-as-a-target-for-nerve-regeneration/
Researchers here show that the gene Lin28 regulates axon regrowth. In mice, raised levels of Lin28 produce greater regeneration of nerve injuries. Past research has investigated Lin28 from the standpoint of producing a more general improvement in regenerative capacity. It improves mitochondri...
Source: Fight Aging! - May 24, 2020 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Some healthcare can safely wait (and some can ’t)
Among the many remarkable things that have happened since the COVID-19 pandemic began is that a lot of our usual medical care has simply stopped.
According to a recent study, routine testing for cervical cancer, cholesterol, and blood sugar is down nearly 70% across the country. Elective surgeries, routine physical examinations, and other screening tests have been canceled or rescheduled so that people can stay at home, avoid being around others who might be sick, and avoid unknowingly spreading the virus. Many clinics, hospitals, and doctors’ offices have been closed for weeks except for emergencies. Even if these facil...
Source: Harvard Health Blog - May 20, 2020 Category: Consumer Health News Authors: Robert H. Shmerling, MD Tags: Health Health care Healthy Aging Men's Health Women's Health Source Type: blogs
Celebrities get shingles, too
Follow me on Twitter @RobShmerling
Perhaps you heard the news recently that Lin-Manuel Miranda has shingles. Headlines announced this in a variety of ways:
Hamilton creator Lin-Manuel Miranda is suffering from shingles (NY DailyNews)
Lin-Manuel Miranda has shingles; must be quarantined from his baby (today.com)
Lin-Manuel Miranda has shingles, regrets joke about blurred vision (CBS News).
Without more information, these headlines might leave you wondering: is this a serious condition? Is it dangerous for children? Can it lead to blindness?
What is shingles?
The term “shingles” refers to a painful rash caused by infec...
Source: Harvard Health Blog - April 11, 2018 Category: Consumer Health News Authors: Robert H. Shmerling, MD Tags: Health Infectious diseases Skin and Hair Care Vaccines Source Type: blogs
How Long Does Shingles Last In The Elderly?
View Original Article Here: How Long Does Shingles Last In The Elderly?
Shingles is a viral infection that follows a varicella-zoster infection, although it can take decades for symptoms of the secondary disease to emerge. The condition presents as a painful and blistering rash, but it is not life-threatening.
According to the Center for Disease Control, there are nearly one million cases in the United States each year, and almost half of those cases are in older adults over age 60. Some people only see one instance of the illness, while others have recurring symptoms, but 30 percent of Americans will develop shingles at s...
Source: Shield My Senior - December 8, 2017 Category: Geriatrics Authors: Vin Tags: Senior Safety Source Type: blogs
